Cellular senescence may influence cancer progression through the (SASP).
SASP includes a variety of bioactive chemicals that can significantly affect the tumor microenvironment.
Initially, SASP can support tumor suppression by drawing immune cells to the tumor and inhibiting cancer cell growth.
However, prolonged SASP presence may contribute to tumor growth, metastasis, and resistance to treatment.
Therapy-induced senescence can lead to increased numbers of senescent cells and a more pro-tumorigenic SASP.
Targeting SASP is being explored as a potential strategy to enhance cancer therapy.
Simplified
Cellular senescence, characterized by partially irreversible cell cycle arrest, has a dual role in cancer progression via the (SASP). SASP encompasses a wide range of bioactive chemicals, including cytokines, chemokines, growth factors, and proteases, all of which can have a significant impact on the tumor microenvironment (TME). Initially, SASP can enhance tumor suppression by attracting immune cells and inhibiting cancer cell proliferation, but its long-term presence at TME can promote tumor growth, metastasis, and treatment resistance. Moreover, therapy-induced senescence, a common side effect of cancer treatments, can result in an increase of senescent cells and pro-tumorigenic SASP. Therefore, recent research has highlighted the potential of targeting SASP to improve cancer therapy. Among the therapeutic strategies, senolytic therapies selectively eliminate senescent cells, whereas senomorphic drugs decrease SASP without cytotoxicity, and there is also combined therapy targeting SASP for oncotherapy. Therefore, it is of crucial importance to develop more specific senotherapeutics and investigate the clinical applications of SASP modulation, such as using SASP components as biomarkers for therapy monitoring and personalized medicine. Taken together, understanding the molecular processes of SASP induction and their function in TME, including its heterogeneity across cell types and tissues, and designing personalized treatment are critical for optimizing cancer therapy and improving patient outcomes.
Full Text
We can’t show the full text here under this license.
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: All authors agree on the publication of this research article. Competing interests: The authors declare no competing interests.
